Relationship between Adipokines and Cardiovascular Ultrasound Parameters in Metabolic-Dysfunction-Associated Fatty Liver Disease

Ismaiel, Abdulrahman; Spînu, Mihail; Budişan, Liviuţa; Leucuţa, Daniel-Corneliu; Popa, Stefan-Lucian; Chiș, Bogdan Augustin; Berindan‐Neagoe, Ioana; Olinic, Dan-Mircea; Dumitraşcu, Dan L.

doi:10.3390/jcm10215194

Cited by 9 publications

(7 citation statements)

References 61 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, patients with NAFLD often have dyslipidemia, which is atherogenic in nature and is defined by elevated serum triglyceride levels and reduced high density lipoproteins cholesterol (HDL-C) levels [ 18 , 19 , 20 ]. Hence, NAFLD patients present an increased CV risk [ 21 , 22 , 23 ]. The atherogenic index of plasma (AIP), a novel quantitative index utilized to assess lipid levels, is a strong marker of dyslipidemia [ 24 , 25 ].…”

Section: Introductionmentioning

confidence: 99%

Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis

et al. 2022

Self Cite

View full text Add to dashboard Cite

(1) Background: Approximately a billion people worldwide are affected by NAFLD, which places a high clinical burden and financial cost on society. Liver biopsy is the gold standard for diagnosing NAFLD, but its invasivity limits the early diagnosis of NAFLD. Hence, it is important to look for alternate techniques in detecting and diagnosing NAFLD. NAFLD is associated with atherosclerosis. The purpose of this study was to assess the effectiveness of the atherogenic index of plasma (AIP) as a non-invasive modality for predicting NAFLD. (2) Methods: A search using electronic databases PubMed, EMBASE, and Scopus was carried out to find observational studies, looking at research that had been published up until the date of 11 May 2022. The included studies’ quality, risk of bias, and internal validity were evaluated using the QUADAS-2 quality assessment tool. The key summary outcomes were the mean difference (MD) and area under the curve (AUC). (3) Results: A total of eight studies (81,178 participants) were included in our review, while 17% of the included participants had NAFLD. A sex distribution of 57.8% men and 42.2% women was observed. The AIP between NAFLD and the controls was not significant (MD 0.212 [95% CI 0.231–0.655]). A significant MD in AIP between the males and females with NAFLD was observed (MD 0.246 [95% CI 0.098–0.395]). The AIP predicted NAFLD with an AUC of 0.764 as well as in males (AUC 0.761) and females (AUC 0.733). (4) Conclusions: There was a substantial MD in the AIP between both sexes, but there was no significant difference in the AIP values between patients with NAFLD and the controls. The AIP is a reliable biomarker for the diagnosis of NAFLD since its ability to predict the development of NAFLD was comparable to that of the other biomarkers.

show abstract

Section: Introductionmentioning

confidence: 99%

Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, elevated lipid levels have been shown to be associated with atherosclerotic disease and coronary artery disease (40). However, Ismaiel et al showed no significant association between serum adiponectin and enadiponectin levels in patients with MAFLD and controls; although E/A was significantly associated with adiponectin in univariate analysis, this association weakened after multivariable linear regression (35). Considering the effects of adiponectin and enadiponectin on CVD, further studies are needed to confirm their effects on cardiovascular risk in patients with MAFLD.…”

Section: Discussionmentioning

confidence: 99%

“…The increased morbidity and all-cause mortality could be attributed to several pathogenic factors, including hormones, nutrition, toxicity of intestinal disorders, insulin resistance, fat, liver inflammation, and gene functions (32-34). Adipose tissue is a highly active endocrine tissue that produces peptide adipocytokines with autocrine, paracrine, and endocrine functions, such as adiponectin and endolipins (35). Adiponectin is the most abundant peptide secreted by adipocytes; it has been found to be secreted by other cells besides endothelial cells, including bone and cardiomyocytes.…”

Section: Discussionmentioning

confidence: 99%

Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis

Wen

Wang

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundMetabolic dysfunction-associated fatty liver disease [MAFLD, formerly known as nonalcoholic fatty liver disease (NAFLD)] is one of the most important causes of liver disease worldwide, while cardiovascular disease (CVD) is still one of the main causes of morbidity and mortality worldwide, and the two are closely related. This study aimed to investigate the risk of CVD incidence or CVD-related mortality (CVD mortality) in patients diagnosed with MAFLD under new concepts and new diagnostic criteria.MethodsWe searched English databases PubMed, Web of Science, Embase, and Cochrane Library for relevant literature. The language was restricted to English.ResultsBy 22 January 2022, 556 published studies were obtained through preliminary retrieval, and 10 cohort studies were included in this study. All statistical analyses were performed using Review Manager 5.2 software. Compared with the control group, patients in the MAFLD group had a significantly higher relative risk of CVD incidence or CVD mortality during the follow-up, with an RR rate of 1.95 (95% CI 1.76–2.17, p < 0.01). The incidence of CVD in the MAFLD group was more than twice that in the control group (RR 2.26, 95% CI 2.00–2.54, p < 0.01). The mortality rate of CVD was 1.57 times higher than that in the control group (RR 1.57, 95% CI 1.42–1.72, p < 0.01).ConclusionsPatients diagnosed with MAFLD alone had higher cardiovascular mortality than those diagnosed with NAFLD alone based on the available data.

show abstract

“…The recruitment process, hepatic steatosis and echocardiographic assessment, as well as the laboratory tests were previously described in details [ 30 , 31 ]. In summary, we performed a cross-sectional observational study, enrolling participants using non-probability consecutive sampling between January 2020 – September 2020.…”

Section: Methodsmentioning

confidence: 99%

MBOAT7 rs641738 variant in metabolic-dysfunction-associated fatty liver disease and cardiovascular risk

Ismaiel

Spînu

Osan

et al. 2022

Medicine and Pharmacy Reports

Self Cite

View full text Add to dashboard Cite

Introduction. Although metabolic-dysfunction-associated fatty liver disease (MAFLD) is associated with an increased cardiovascular risk, MAFLD predisposing genetic variants were not steadily related to cardiovascular events. Therefore, we aimed to assess whether membrane-bound O-acyltransferase domain-containing 7 (MBOAT7) rs641738 variant is associated with an increased cardiovascular risk in in MAFLD patients. Methods. We conducted an observational cross-sectional study including 77 subjects (38 MAFLD patients, 39 controls), between January-September 2020 using hepatic ultrasonography and SteatoTestTM to assess hepatic steatosis. Echocardiographic and Doppler ultrasound parameters were evaluated. Genomic DNA was extracted and rs641738 SNP was genotyped using TaqMan assays. Results. The rs641738 variant was not significantly associated with MAFLD, with a p-value of 0.803, 0.5265, 0.9535, and 0.5751 for codominant, dominant, recessive, and overdominant genotypes, respectively. The rs641738 variant overdominant genotype significantly predicted atherosclerotic cardiovascular disease (ASCVD) risk algorithm in univariate analysis (-4.3 [95% CI -8.55 – -0.55, p-value= 0.048]), but lost significance after multivariate analysis (-3.98 [95% CI -7.9 – -0.05, p-value= 0.053]). The rs641738 variant recessive genotype significantly predicted ActiTest in univariate analysis (0.0963 [95% CI 0.0244 – 0.1681, p-value= 0.009]), but lost significance after multivariate analysis (0.0828 [95% CI -0.016 – 0.1816, p-value= 0.105]). Conclusion. No significant association was observed between rs641738 variant and MAFLD in the studied population. The rs641738 variant was found to predict ASCVD risk score and ActiTest in univariate linear regression analysis. However, the significance of both associations was lost after performing multivariate analysis.

show abstract

Relationship between Adipokines and Cardiovascular Ultrasound Parameters in Metabolic-Dysfunction-Associated Fatty Liver Disease

Cited by 9 publications

References 61 publications

Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis

Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis

Metabolic dysfunction-associated fatty liver disease and cardiovascular disease: A meta-analysis

MBOAT7 rs641738 variant in metabolic-dysfunction-associated fatty liver disease and cardiovascular risk

Contact Info

Product

Resources

About